Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    789.87
    +6.17 (+0.79%)
     
  • GBP/EUR

    1.1627
    +0.0016 (+0.14%)
     
  • GBP/USD

    1.2529
    +0.0005 (+0.04%)
     
  • Bitcoin GBP

    48,378.69
    -1,535.39 (-3.08%)
     
  • CMC Crypto 200

    1,256.27
    -101.74 (-7.49%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • DOW

    39,512.84
    +125.08 (+0.32%)
     
  • CRUDE OIL

    78.28
    -0.98 (-1.24%)
     
  • GOLD FUTURES

    2,370.40
    +30.10 (+1.29%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

Abbvie stock falls amid growing biosimilar competition

Pharmaceutical giant AbbVie Inc. (ABBV) shares came under pressure as the market closed on Friday, following the disappointing first quarter sales performance of the company's arthritis drug, Humira. The company forecast that Humira's sales could slow further in the face of heightened competition.

Yahoo Finance's health reporter Anjalee Khemlani breaks down the details, providing insight into the rise of biosimilars in the market.

For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance.

This post was written by Angel Smith